Short-term ethinylestradiol treatment suppresses inferior caval vein thrombosis in obese mice

Summary

Obesity and oral estrogens are independent risk factors for venous thrombosis, and their combined effect is stronger than the sum of the isolated factors. It was the objective of this study to investigate the interaction between obesity and estrogens at the level of venous thrombotic tendency, coagulation and inflammation in a mouse model.Female C57Bl/6J mice were fed a standard fat diet (SFD) or a high fat diet (HFD) to induce nutritional obesity.After 14 weeks, while maintaining their diet, mice were orally treated eight days with 1 µg ethinylestradiol or vehicle (n=25 per group), and subsequently subjected to an inferior caval vein (ICV) thrombosis model.The ICV thrombosis model resulted in an increased thrombus weight in vehicle-treated HFD mice (3.0 ± 0.7 mg) compared to vehicle-treated SFD mice (1.4 ± 0.4 mg; p=0.064). Surprisingly, estrogens reduced thrombus weight, which was significant for the HFD group (0.8 ± 0.5 mg; p=0.013).As compared to SFD feeding, HFD feeding significantly increased plasma levels of coagulation factor VIII, combined factor II/VII/X (p<0.001), and plasminogen activator inhibitor-1 (p=0.009), causing a prothrombotic shift of the coagulation profile. Estrogens had no significant effects on this profile with either diet,whereas serum amyloidA and hepatic inflammatory cytokines were minimally affected.The synergistic effect of obesity and estrogens on the venous thrombotic risk in women could not be translated into the mouse context. Short-term ethinylestradiol administration in a mouse ICV thrombosis model counteracts the prothrombotic phenotype associated with nutritionally induced obesity, despite a comparable activated plasma coagulation profile in estrogen-treated and untreated obese mice.

Keywords

Estrogens - mouse models - obesity - venous thrombosis

• References

• 1 Abdollahi M, Cushman M, Rosendaal FR. Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. Thromb Haemost 2003; 89: 493-498.
• 2 Darvall KA, Sam RC, Silverman SH. et al. Obesity and thrombosis. Eur J Vasc Endovasc Surg 2007; 33: 223-233.
• 3 Oren E, Smith NL, Doggen CJ. et al. Body mass index and the risk of venous thrombosis among postmenopausal women. J Thromb Haemost 2006; 04: 2273-2275.
• 4 Pomp ER, le Cessie S, Rosendaal FR. et al. Risk of venous thrombosis: obesity and its joint effect with oralcontraceptive use and prothrombotic mutations. Br J Haematol 2007; 139: 289-296.
• 5 Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Female hormones and thrombosis. Arterioscler Thromb Vasc Biol 2002; 22: 201-210.
• 6 Stein PD, Beemath A, Olson RE. Obesity as a risk factor in venous thromboembolism. Am J Med 2005; 118: 978-980.
• 7 Canonico M, Oger E, Conard J. et al. Obesity and risk of venous thromboembolism among postmenopausal women: differential impact of hormone therapy by route of estrogen administration The ESTHER Study. J Thromb Haemost 2006; 04: 1259-1265.
• 8 Canonico M, Oger E. Plu-Bureau, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007; 115: 840-845.
• 9 Koh KK, Yoon BK. Controversies regarding hormone therapy: Insights from inflammation and hemostasis. Cardiovasc Res 2006; 70: 22-30.
• 10 Silvestri A, Gebara O, Vitale C. et al. Increased levels of C-reactive protein after oral hormone replacement therapy may not be related to an increased inflammatory response. Circulation 2003; 107: 3165-3169.
• 11 Vehkavaara S, Silveira A, Hakala-Ala-Pietila T. et al. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb Haemost 2001; 85: 619-625.
• 12 Zegura B, Guzic-Salobir B, Sebestjen M. et al. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women. Menopause 2006; 13: 643-650.
• 13 Bodary PF, Vargas FB, King SA. et al. Pioglitazone protects against thrombosis in a mouse model of obesity and insulin resistance. J Thromb Haemost 2005; 03: 2149-2153.
• 14 Konstantinides S, Schafer K, Neels JG. et al. Inhibition of endogenous leptin protects mice from arterial and venous thrombosis. Arterioscler Thromb Vasc Biol 2004; 24: 2196-2201.
• 15 Nagai N, Lijnen HR, Cleuren AC. et al. Factor V Leiden mutation is associated with enhanced arterial thrombotic tendency in lean but not in obese mice. Thromb Haemost 2007; 98: 858-863.
• 16 Nagai N, Hoylaerts MF, Cleuren AC. et al. Obesity promotes injury induced femoral artery thrombosis in mice. Thromb Res 2008; 122: 549-555.
• 17 Tchaikovski SN, van Vlijmen BJ, Rosing J. et al. Development of a calibrated automated thrombography based thrombin generation test in mouse plasma. J Thromb Haemost 2007; 05: 2079-2086.
• 18 Singh I, Smith A, Vanzieleghem B. et al. Antithrombotic effects of controlled inhibition of factor VIII with a partially inhibitory human monoclonal antibody in a murine vena cava thrombosis model. Blood 2002; 99: 3235-3240.
• 19 Day SM, Reeve JL, Myers DD. et al. Murine thrombosis models. Thromb Haemost 2004; 92: 486-494.
• 20 Declerck PJ, Verstreken M, Collen D. Immunoassay of murine t-PA, u-PA and PAI-1 using monoclonal antibodies raised in gene-inactivated mice. Thromb Haemost 1995; 74: 1305-1309.
• 21 terHorst SA, Fijlstra M, Sengupta S. et al. Spatial and temporal expression of surfactant proteins in hyperoxia-induced neonatal rat lung injury. BMC Pulm Med 2006; 06: 8.
• 22 Moverare S, Skrtic S, Lindberg MK. et al. Estrogen increases coagulation factor V mRNA levels via both estrogen receptor-alpha and -beta in murine bone marrow/bone. Eur J Endocrinol 2004; 151: 259-263.
• 23 Yamamoto Y, Moore R, Hess HA. et al. Estrogen receptor alpha mediates 17alpha-ethynylestradiol causing hepatotoxicity. J Biol Chem 2006; 281: 16625-16631.
• 24 Abu-Fanne R, Brzezinski A, Golomb M. et al. Effects of estradiol and raloxifene on arterial thrombosis in ovariectomized mice. Menopause 2008; 15: 98-104.
• 25 Koh KK. Effects of estrogen on the vascular wall: vasomotor function and inflammation. Cardiovasc Res 2002; 55: 714-726.
• 26 Leng XH, Zhang W, Nieswandt B. et al. Effects of estrogen replacement therapies on mouse platelet function and glycoprotein VI levels. Circ Res 2005; 97: 415-417.
• 27 Quehenberger P, Kapiotis S, Partan C. et al. Studies on oral contraceptive-induced changes in blood coagulation and fibrinolysis and the estrogen effect on endothelial cells. Ann Hematol 1993; 67: 33-36.
• 28 Simoncini T, Mannella P, Genazzani AR. Rapid estrogen actions in the cardiovascular system. Ann NY Acad Sci 2006; 1089: 424-430.
• 29 Fox SW, Chambers TJ. The effect of oestrogen on megakaryocyte differentiation and platelet counts in vivo. Int J Cardiol 2006; 109: 359-366.
• 30 Moro L, Reineri S, Piranda D. et al. Nongenomic effects of 17beta-estradiol in human platelets: potentiation of thrombin-induced aggregation through estrogen receptor beta and Src kinase. Blood 2005; 105: 115-121.
• 31 Moorthy K, Sharma D, Basir SF. et al. Administration of estradiol and progesterone modulate the activities of antioxidant enzyme and aminotransferases in naturally menopausal rats. Exp Gerontol 2005; 40: 295-302.